Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory conditions that have been linked to an increased risk of major adverse cardiovascular events (MACE).1 Recent research has investigated the comparative effects of biologic and nonbiologic systemic therapies on the incidence of both new-onset and recurrent MACE in affected patients. A study published in TheJournal of the American Academy of Dermatology provided an objective analysis of a retrospective cohort study assessing this association and its clinical implications.2
Researchers behind the study concluded that, “biologic therapy in patients with psoriasis or PsA offers protective effects against MACEs, regardless of MACE history. This suggests that biologic therapies should be actively considered not only for their efficacy in managing psoriasis or…